Monday, June 14, 2021 Daily Archives

CDMO Yposkesi adding two viral vector lines in $71m expansion

With Korean investment firm SK Holdings on board, CDMO Yposkesi is building a second commercial manufacturing plant to support the burgeoning gene therapy sector. Contract development and manufacturing organization (CDMO) Yposekesi announced ‘project SKY’ today, investing €58 million ($71 million) in a 50,000 square-foot facility at its site in Corbeil-Essonnes, France – about 40 km south of Paris. Once complete in 2023, the facility will double the CDMO’s production capacity for drug substance of viral vectors and make the Corbeil-Essonnes…

Entegris invests $30m to expand life sciences capabilities

To address increased demand for bioprocessing assemblies, Entegris will invest $30 million to expand three manufacturing facilities. The material and process solutions firm Entegris will expand three of its life sciences manufacturing sites located in Billerica; Massachusetts, Bloomington; Minnesota, and Logan; Utah. “This expansion is in response to the increased pharmaceutical demand for single use high purity bulk systems, especially the ones for freezing, transporting, storing, and thawing drug substances. And obviously, there’s a big challenge for the COVID-19 vaccines,”…

GenScript to distribute Calidi’s ‘trojan horse’ cell therapy tech

GenScript ProBio will promote and advertise Calidi Biotherapeutics’ allogeneic cell technology platform SNV-1 to current and future clients. Under the terms of the agreement, Calidi will train and equip the Genscript sales team to present its SuperNova-1 (SNV-1) technology to their current customers. According to the firm, it recognizes the problems that surround oncolytic viruses as the immune system of the patient attacks and eliminates a large amount of the oncolytic virus from the body. “In many cases, 95%+ of…

COVID-19 driven CDMO investments to benefit wider sector

COVID-19 driven investments in vaccine production capacity will help relieve existing bottlenecks as the pandemic recedes, according to the authors of a new report. Demand for vaccine production capacity increased significantly last year as pharmaceutical industry efforts to develop effective jabs accelerated. The contract development and manufacturing organization (CDMO) sector’s response has been to invest in vaccine and vector production capacity, says Fiona Barry from GlobalData. “We’re seeing very high investment in vaccine-related contract manufacturing, by dedicated CDMOs and by…